New Therapies for ARMD 1 Thursday 17 May 14:30 - 16:00 Salle Camille Blanc
J. Mones,
SPAIN
Quantification of visual acuity improvements over 2 years in the MARINA and ANCHOR studies of intravitreal ranibizumab
Purpose: To report the course of VA gains during the Phase III MARINA and ANCHOR studies of patients with CNV lesions secondary to AMD. These studies were designed to investigate the efficacy and safety of monthly intravitreal injections of ranibizumab over 2 years. Setting: Two phase III, randomized, controlled studies in a total of 1139 patients with choroidal neovascularization secondary to AMD. Methods: Patients were randomized in MARINA to receive monthly intravitreal ranibizumab 0.3mg (n=238) or 0.5mg (n=240), or sham (n=238) for a period of 2 years. Patients were randomized in ANCHOR to receive monthly intravitreal ranibizumab 0.3mg (n=140) or 0.5mg (n=140) plus sham PDT, or verteporfin PDT (n=143) plus sham intravitreal injections for a period of 2 years. Visual acuity (VA) was assessed at monthly intervals using ETDRS charts. Results: In MARINA, patients receiving ranibizumab 0.3mg or 0.5mg, 71 and 70% respectively showed VA gains (>0 letters) at 24 months vs 22% with sham; gains of > or = 5 letters by 55每59%, vs 16%, gains of > or = 10 letters by 42每45%, vs 8%; gains of > or = 15 letters by 26每33% vs 4%, gains of > or = 20 letters by 15每20% vs 2%, gains of > or = 25 letters by 7每12% vs 1%, and gains of > or = 30 letters by 5每6% vs 0%. Corresponding 2 year results from the ANCHOR study are currently being analysed and will be presented at this meeting. Conclusions: Assessment of VA over time showed mean improvements in the ranibizumab treatment arms that were evident by day 7 and continued through month 24. Treatment with intravitreal ranibizumab 0.3mg or 0.5mg is associated with significant improvements in vision which are maintained for at least up to two years. Financial disclosure: Yes
